French, U.S. Health Agencies Take Action Against Actos (Pioglitazone)
In June, the French Agency for the Safety of Health Products pulled Actos (Pioglitazone) from the market. Just six days later, the U.S. Food and Drug Administration (FDA) took the less aggressive – but no less meaningful – step in announcing that Actos use for longer than a year had been associated with an increased risk of bladder cancer. In a press release, the FDA also advised that “The benefits of [Actos] should be weighed against the unknown risks for cancer recurrence.”
Actos is bad news for many, many patients. Do you have diabetes? Has your doctor prescribed Actos to you? If so, it may be time to ask about the consequences of Actos ingestion! In a study in which nearly 200,000 diabetes patients participated, Actos patients who had taken the drug for twelve months or more had a forty percent increased risk for bladder cancer.
Fears | Nachawati is gearing up for a fight against the manufacturer of Actos (Pioglitazone). Have you been hurt as a result of prolonged pioglitazone ingestion? Find out if your eligible to join in our fight! For a free consultation, call us at 1.866.545.8364 or email firstname.lastname@example.org. We’re ready to fight for you!